APGE · Categories · Coverage
APGE - Analyst coverage initiated
Apogee Therapeutics Inc. (APGE) analyst coverage initiated - real-time wire coverage filtered to Coverage only.
Recent Coverage for APGE
- Rothschild & Co Redburn initiated coverage on Apogee Therapeutics with a new price targetRothschild & Co Redburn initiated coverage of Apogee Therapeutics with a rating of Buy and set a new price target of $140.00
- Truist initiated coverage on Apogee Therapeutics with a new price targetTruist initiated coverage of Apogee Therapeutics with a rating of Hold and set a new price target of $83.00
- Wolfe Research initiated coverage on Apogee TherapeuticsWolfe Research initiated coverage of Apogee Therapeutics with a rating of Peer Perform
- Stephens initiated coverage on Apogee Therapeutics with a new price targetStephens initiated coverage of Apogee Therapeutics with a rating of Overweight and set a new price target of $95.00
- Deutsche Bank initiated coverage on Apogee Therapeutics with a new price targetDeutsche Bank initiated coverage of Apogee Therapeutics with a rating of Buy and set a new price target of $103.00
- Craig Hallum initiated coverage on Apogee Therapeutics with a new price targetCraig Hallum initiated coverage of Apogee Therapeutics with a rating of Buy and set a new price target of $109.00
- Mizuho initiated coverage on Apogee Therapeutics with a new price targetMizuho initiated coverage of Apogee Therapeutics with a rating of Outperform and set a new price target of $105.00
- RBC Capital Mkts initiated coverage on Apogee Therapeutics with a new price targetRBC Capital Mkts initiated coverage of Apogee Therapeutics with a rating of Outperform and set a new price target of $60.00
- Citigroup initiated coverage on Apogee Therapeutics with a new price targetCitigroup initiated coverage of Apogee Therapeutics with a rating of Buy and set a new price target of $95.00
- Canaccord Genuity initiated coverage on Apogee Therapeutics with a new price targetCanaccord Genuity initiated coverage of Apogee Therapeutics with a rating of Buy and set a new price target of $89.00
- BofA Securities initiated coverage on Apogee Therapeutics with a new price targetBofA Securities initiated coverage of Apogee Therapeutics with a rating of Buy and set a new price target of $80.00
- BTIG Research initiated coverage on Apogee Therapeutics with a new price targetBTIG Research initiated coverage of Apogee Therapeutics with a rating of Buy and set a new price target of $43.00
- TD Cowen initiated coverage on Apogee TherapeuticsTD Cowen initiated coverage of Apogee Therapeutics with a rating of Outperform
- Wedbush initiated coverage on Apogee Therapeutics with a new price targetWedbush initiated coverage of Apogee Therapeutics with a rating of Outperform and set a new price target of $40.00
- Guggenheim initiated coverage on Apogee Therapeutics with a new price targetGuggenheim initiated coverage of Apogee Therapeutics with a rating of Buy and set a new price target of $29.00
- Stifel initiated coverage on Apogee Therapeutics with a new price targetStifel initiated coverage of Apogee Therapeutics with a rating of Buy and set a new price target of $34.00
- Jefferies initiated coverage on Apogee Therapeutics with a new price targetJefferies initiated coverage of Apogee Therapeutics with a rating of Buy and set a new price target of $29.00